All In Biotech

NDA 211962 · Hikma

Tyzavan

Vancomycin Hydrochloride · Intravenous · Glycopeptide Antibacterial

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Feb 15, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

58,342

53,932 serious, 11,489 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 19, 2026.

TYZAVAN is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: Septicemia ( 1.1 ) Infective Endocarditis ( 1.2 ) Skin and Skin Structure Infections ( 1.3 ) Bone Infections ( 1.4 ) Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN and other antibacterial drugs, TYZAVAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Septicemia TYZAVAN is indicated in adults and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of septicemia due to: Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci. Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.2 Infective Endocarditis TYZAVAN is indicated in adults and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of infective endocarditis due to: Susceptible isolates of MRSA. Viridans group streptococci Streptococcus gallolyticus (previously known as Streptococcus bovis ), Enterococcus species and Corynebacterium species. For enterococcal endocarditis, use TYZAVAN in combination with an aminoglycoside. Methicillin-susceptible...

Mechanism: Vancomycin is an antibacterial drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 2025 Supplement 17 · Efficacy LetterLabel
  • May 28, 2021 Supplement 9 · Efficacy LetterLabel
  • Feb 15, 2019 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
7 products under this application
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 2GM BASE/400ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1GM BASE/200ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 750MG BASE/150ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 500MG BASE/100ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6,607
  • acute kidney injury4,422
  • off label use4,327
  • pyrexia3,646
  • drug reaction with eosinophilia and systemic symptoms2,411
  • renal failure2,243
  • diarrhoea2,123
  • sepsis2,115
  • condition aggravated1,970
  • pneumonia1,959
  • hypotension1,948
  • rash1,882

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004798
2005863
2006930
2007720
2008847
2009931
20101,241
20111,805
20121,749
20131,667
20141,787
20152,199
20162,602
20173,174
20184,303
20194,023
20204,815
20214,489
20223,937
20234,011
20244,398
20254,351
20262,698

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.